Sudeep Pharma Ltd made an impressive market debut on Friday, listing with a sharp premium over its issue price following one of the most heavily subscribed IPOs.
The stock began trading at ₹733.95 on the BSE, a 23.7 per cent premium to the IPO price of ₹593. On the NSE, it opened at ₹730, reflecting a 23 per cent premium, setting a strong tone for its first day of trade.
The has rung in the celebration of the listing of Sudeep Pharma Limited at our exchange .
— NSE India (@NSEIndia)
Post-listing, the stock fluctuated between ₹725-₹777.25.
At 10.24 am, it traded at ₹766 and ₹766.70 on the BSE and NSE, respectively, 29 per cent above the offer price.
Heavily subscribed ₹895 crore-IPO
The company’s ₹895-crore initial public offering witnessed overwhelming investor demand, closing with on the final day. The response was particularly strong from institutional investors, with the QIBs category subscribed 213.08 times. Non-institutional investors subscribed 116.72 times, while the retail portion was booked 15.65 times.
Sudeep Pharma had earlier raised ₹268.5 crore from anchor investors. The price band for the offer was set at ₹563–593 per equity share. The IPO comprised a fresh issue of ₹95 crore and an offer-for-sale (OFS) of nearly 1.35 crore equity shares amounting to ₹800 crore by the promoters.
Sudeep Pharma, a technology-led manufacturer of excipients and speciality ingredients catering to the pharmaceutical, food, and nutrition sectors, has positioned itself as a key contributor to the global healthcare ecosystem. The company’s strong fundamentals, expanding product portfolio, and consistent industry demand were among the factors driving positive expectations for its listing.